Stifel Downgrades Evofem Biosciences to Hold, Lowers Price Target to $0.5
Stifel analyst Annabel Samimy downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold and lowers the price target from $3 to $0.5.
Why Evofem Biosciences Shares Are Plunging Today?
Evofem Biosciences Inc's (OTC: EVFM) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100) to prevent chlamydia and gonorrhea infection in women but did not achieve its endpoints.
Evofem Announces Issuance Of U.S. Patent Covering Phexxi Composition Of Matter; Newly Issued Patent Expected To Provide Protection For Phexxi Into At Least 2033
-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio --
-- Newly Issued Patent Expected to Provide Protection for Phexxi into At Least 2033 --
SAN
‘West Virginia governor signs abortion ban, making state the second to enact abortion restrictions since Roe overturned.’ – Tweet By Zeke Miller
https://twitter.com/ZekeJMiller/status/1570831511469060096
4 Analysts Have This to Say About Evofem Biosciences
Over the past 3 months, 4 analysts have published their opinion on Evofem Biosciences (OTC:EVFM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.
Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday’s Mid-Day Session
Gainers
Assure Holdings Corp. (NASDAQ: IONM) shares jumped 88.8% to $3.9650 after jumping around 104% on Thursday.